Arena Pharmaceuticals Investigated By Goldfarb Branham Law Firm LLP
Goldfarb Branham LLP is investigating shareholder claims against officers and directors of Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) due to the revelation that the FDA advisory panel voted against approval of an Arena drug called Lorcaserin. Shareholders are encouraged to contact the firm at 877-583-2855 or hlindley@goldfarbbranham.com to learn about their rights.
“The Food and Drug Administration issued a document that questioned the safety and efficacy of Arena’s Lorcaserin drug,” said securities attorney Hamilton Lindley. “That FDA document revealed, among other things, that the drug was associated with malignant tumors in rats. After this news and a report that the FDA advisory panel reportedly rejected Lorcaserin due to concerns with the potential safety problems, Arena stock has dropped 87 percent.”
Goldfarb Branham LLP is investigating a derivative lawsuit against
company officers and directors for allowing this to occur. Derivative
lawsuits often lead to restored confidence in companies involved in
financial scandal and a resulting increase in shareholder value.
Concerned shareholders who still hold their shares are urged to contact
attorney Hamilton Lindley at 877-583-2855 or
hlindley@goldfarbbranham.com.
Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
TheStreet Quant Ratings
TRY IT FREENew! $49.95/yr
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
Product Features:
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Dividend Stock Advisor
TRY IT FREEJim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
